Newsroom

Recent news, statements, and resources

Newsroom

Recent news, statements, and resources

Welcome to The Leukemia & Lymphoma Society Newsroom

Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.

The Leukemia & Lymphoma Society Receives $17 Million from the Mike and Sofia Segal Family Foundation to Accelerate Progress in the Treatment of Chronic Myelomonocytic Leukemia

October 24, 2023

The Leukemia & Lymphoma Society's Response to the Israel-Hamas War

October 12, 2023

FDA approves momelotinib (Ojjaara™) for myelofibrosis and anemia

FDA Approves Treatment for Myelofibrosis and Anemia

September 29, 2023

FDA approval gives more myeloma patients chance at long-term remission

Recent FDA Approval Gives More Myeloma Patients Chance at Long-Term Remission with a Stem Cell Transplant

September 28, 2023

man and woman

White House Highlights The Leukemia & Lymphoma Society’s Efforts to Bring Clinical Trials and Treatment Innovation to Diverse and Underrepresented Communities Nationwide in Alignment with the Biden-Harris Administration's Cancer Moonshot

September 13, 2023

ltn

The Leukemia & Lymphoma Society’s Light The Night Events Lead the Charge Against Blood Cancer

September 13, 2023

The Leukemia & Lymphoma Society joins the GVHD Alliance to provide support and bring hope to people living with graft-versus-host disease.

GVHD Alliance Commemorates Blood Cancer Awareness Month: Welcomes The Leukemia & Lymphoma Society, Announces Meredith A. Cowden Patient Advocacy Achievement Award

September 12, 2023

September is Blood Cancer Awareness Month

NEW SURVEY FROM THE LEUKEMIA & LYMPHOMA SOCIETY REVEALS LOW AWARENESS ABOUT BLOOD CANCERS

August 30, 2023

LLS Applauds FDA’s Expanded Approval of Medication to Treat Blood Disorder in Adults with Myelodysplastic Syndromes

LLS Applauds FDA’s Expanded Approval of Medication to Treat Blood Disorder in Adults with Myelodysplastic Syndromes

August 29, 2023

Media Requests

For all media-related inquiries and interview requests please email mediarelations@lls.org. An LLS representative will respond as soon as possible.